Home/Filings/4/0001209191-23-002670
4//SEC Filing

Kenny Kevin J. 4

Accession 0001209191-23-002670

CIK 0000884624other

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 7:19 PM ET

Size

17.5 KB

Accession

0001209191-23-002670

Insider Transaction Report

Form 4
Period: 2023-01-05
Kenny Kevin J
President of Global Spine
Transactions
  • Award

    Common Stock

    2023-01-05+12,229125,026 total
  • Award

    Common Stock

    2023-01-05+10,485112,797 total
  • Award

    Common Stock

    2023-01-05+20,492145,518 total
  • Award

    Common Stock

    2023-01-05+29,905102,312 total
  • Award

    Employee Stock Option (Right to Buy)

    2023-01-05+72,14672,146 total
    Exercise: $20.90Exp: 2033-01-05Common Stock (72,146 underlying)
Footnotes (6)
  • [F1]The restricted stock units vest with respect to one-fourth (1/4th) of the shares of stock covered hereby on each of the first, second, third, and fourth anniversaries of the Grant Date.
  • [F2]Represents outstanding performance stock units for awards granted in 2020, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on June 8, 2023.
  • [F3]Represents outstanding performance stock units for awards granted in 2021, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on April 1, 2024.
  • [F4]Represents outstanding performance stock units for awards granted in 2022, which as a result of the Orthofix Board's determination to treat the merger with SeaSpine Holdings Corporation as a change in control (referred to as a "corporate transaction" under Orthofix's Amended and Restated 2012 Long-Term Incentive Plan) were deemed achieved at target levels as of the merger date and converted to time-based awards that vest on January 31, 2025.
  • [F5]Includes 124,049 unvested restricted stock units.
  • [F6]The option vests in four equal installments on each of January 5, 2023, January 5, 2024, January 5, 2025 and January 5, 2026.

Issuer

Orthofix Medical Inc.

CIK 0000884624

Entity typeother

Related Parties

1
  • filerCIK 0001520400

Filing Metadata

Form type
4
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 7:19 PM ET
Size
17.5 KB